Kyle J. MacBeth

Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS

Jan Krönke, Emma C. Fink, Paul W. Hollenbach et al. · Nature · 2015 · 836 citations · Full text

Medicine, Molecular Biology, Oncology +8

A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines

Paul W. Hollenbach, Aaron Nguyen, Helen Brady et al. · PLoS ONE · 2010 · 357 citations · Full text

Medicine, Oncology, Pharmacology +16

Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib

Eytan M. Stein, Courtney D. DiNardo, Amir T. Fathi et al. · Blood · 2018 · 329 citations · Full text

Medicine, Hematology, Oncology +13

Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia

Guillermo Garcia‐Manero, Steven D. Gore, Christopher R. Cogle et al. · Journal of Clinical Oncology · 2011 · 250 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia

Daniel A. Pollyea, Martin S. Tallman, Stéphane de Botton et al. · Leukemia · 2019 · 250 citations · Full text

Medicine, Oncology, Pharmacology +14